新型sGC刺激剂维立西呱在心衰治疗中的价值
Value of a novel sGC stimulant Vericygide in the treatment of heart failure
潘靖 1梅易异 1许盛松1
作者信息
- 1. 上饶市人民医院心血管内科,江西 上饶 334000
- 折叠
摘要
目的:探讨新型可溶性鸟苷酸环化酶(sGC)刺激剂维立西呱在心衰(HF)治疗中的价值.方法:2022 年10 月～2023 年 6 月本院收治的 60 例HF患者,随机数字表法分为维立西呱组和对照组,每组各 30 例.对照组采用常规抗HF治疗,维立西呱组在对照组基础上给予维立西呱口服,均持续 3 m.比较两组的心功能改善疗效和治心室重构指标、心功能及不良反应发生率.结果:维立西呱组心功能改善疗效为 93.33%,高于对照组的 73.33%(P＜0.05).维立西呱组LVEF、6MWT高于对照组,LVESV、LVEDD和NT-ProBNP低于对照组(P＜0.05).结论:新型sGC刺激剂维立西呱治疗可改善HF患者心功能和运动耐力,降低NT-ProBNP水平.
Abstract
Objective:To investigate the value of vericypiac,a novel soluble guanylate cyclase(sGC)stimulator,in the treatment of heart failure(HF).Methods:From October 2022 to June 2023,60 patients with HF admitted to our hospital were divided into Vericygua group and control group by machine digital table method,with 30 cases in each group.The control group received conventional anti-HF treatment,and the vericigua group received oral vericigua on the basis of the control group,all of which lasted for 3 months.The effects of improving cardiac function,treating ventricular remodeling index,cardiac function and incidence of adverse reactions were compared between the two groups.Results:The improvement effect of heart function in vericiquide group was 93.33%,which was higher than that in control group(73.33%,P<.05).LVEF and 6MWT of vericygua group were higher than those of control group,LVESV,LVEDD and NT-ProBNP of Vericygua group were lower than those of control group(P<0.05).Conclusion:Vericygide,a new type of sGC stimulator,can improve the cardiac function and exercise endurance of HF patients,and reduce the level of NT-ProBNP.
关键词
可溶性鸟苷酸环化酶刺激剂/维立西呱/心衰/心功能改善疗效Key words
Soluble guanylate cyclase stimulator/Veliciqua/Heart failure/Cardiac function improvement effect引用本文复制引用
基金项目
上饶市科技支撑计划(2022CZDX05)
出版年
2024
NETL
NSTL
维普
万方数据